promo_leaderboard Ad
‹ All stocks
ELVN

Enliven Therapeutics

ELVN · NASDAQ · Healthcare
$46.58
▼ $1.04 (-2.19%)
$46.58 $46.91 $47.25 $47.58 $46.58 21:32 15:02
Day range
$46.34 – $47.75
Year range
$14.79 – $62.32
Open
$47.61
Previous close
$47.62
Market cap
$3.43B
Volume (24h)
$30.0K
Volume (52w)
$1.40M
Performance
7D
▼ -9.03%
1M
▲ 20.36%
3M
▼ -21.57%
6M
▲ 10.24%
1Y
▲ 114.05%
YTD
▲ 199.73%
3Y
▲ 341.91%
5Y
▲ 247.59%
All-time
▼ -22.37%
Key statistics
P/E ratio
-27.24
EPS (TTM)
$-1.71
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
73.6M
About Enliven Therapeutics

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

Visit website
Country: United States of America
More in Healthcare